AEON Biopharma, Inc. (AEON) 10-Year Financial Performance & Capital Metrics

AEON • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

AboutAEON Biopharma, Inc., a biopharmaceutical company, focuses on the development botulinum toxins for the treatment of debilitating medical conditions. It also develops 900 kDabotulinum toxin complex, ABP-450, for migraine, cervical dystonia, and gastroparesis. The company was formerly known as ALPHAEON Corporation and changed its name to AEON Biopharma, Inc. in December 2019. AEON Biopharma, Inc. was incorporated in 2012 and is headquartered in Newport Beach, California.Show more

Revenue $0
EBITDA $73M +121.0%
Net Income $42M +110.9%
EPS (Diluted) 72.93 +1561.5%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -
ROIC -
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 88 (top 12%)
✓Share count reduced 99.3% through buybacks

✗Weaknesses

✗Profits declining 24.6% over 5 years
✗Weak Piotroski F-Score: 3/9
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-24.65%

3Y-

TTM-100.02%

EPS CAGR

10Y-

5Y-45.24%

3Y-

TTM-65.41%

ROCE

10Y Avg-1685.32%

5Y Avg-2500.12%

3Y Avg-

Latest-

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
JAZZJazz Pharmaceuticals plc	10.4B	171.16	19.79	6.12%	-8.86%	-9.31%	12.96%	1.51
ACADACADIA Pharmaceuticals Inc.	4.49B	26.53	19.51	31.85%	24.94%	28.47%	3.5%	0.07
CPRXCatalyst Pharmaceuticals, Inc.	2.82B	22.96	17.53	23.49%	37.63%	23.64%	8.48%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.1B	36.41	14.51	22.8%	22.48%	22.23%	10.43%	0.28
ALKSAlkermes plc	5.15B	31.22	14.39	-6.36%	22.27%	19.55%	7.87%	0.05
PRTCPureTech Health plc	463.31M	19.17	9.59	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	540.89M	21.38	-1.20
NMRANeumora Therapeutics, Inc. Common Stock	361.97M	2.13	-1.39			-178.79%		0.01

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	3.36M	2.52M	0	0	0	0
Revenue Growth %	-	-0.25%	-1%	-	-	-
Cost of Goods Sold+	1K	0	0	0	0	0
COGS % of Revenue	0%	-	-	-	-	-
Gross Profit+	3.36M	2.52M	0	0	0	0
Gross Margin %	1%	1%	-	-	-	-
Gross Profit Growth %	-	-0.25%	-1%	-	-	-
Operating Expenses+	57.32M	18.91M	65.85M	48.43M	348.09M	-72.98M
OpEx % of Revenue	17.08%	7.51%	-	-	-	-
Selling, General & Admin	46.04M	11.59M	11.15M	13.68M	19.79M	13.64M
SG&A % of Revenue	13.71%	4.6%	-	-	-	-
Research & Development	4.81M	7.32M	25.73M	34.75M	33.05M	14.18M
R&D % of Revenue	1.43%	2.91%	-	-	-	-
Other Operating Expenses	6.47M	0	28.97M	0	295.25M	-100.81M
Operating Income+	-53.97M	-16.39M	-65.85M	-48.43M	-348.09M	72.98M
Operating Margin %	-16.08%	-6.51%	-	-	-	-
Operating Income Growth %	-	0.7%	-3.02%	0.26%	-6.19%	1.21%
EBITDA+	-53.09M	-15.51M	-65.84M	-48.36M	-347.99M	73.08M
EBITDA Margin %	-15.82%	-6.16%	-	-	-	-
EBITDA Growth %	-	0.71%	-3.24%	0.27%	-6.2%	1.21%
D&A (Non-Cash Add-back)	875K	875K	3K	68K	99K	97K
EBIT	-48.37M	-16.39M	-36.88M	-48.43M	-52.84M	-27.82M
Net Interest Income+	-6.75M	-15K	0	0	0	0
Interest Income	720K	0	0	0	0	0
Interest Expense	7.47M	15K	0	0	0	0
Other Income/Expense	199.64M	-16.52M	10.21M	-4.13M	-36.55M	-30.98M
Pretax Income+	145.67M	-32.91M	-55.64M	-52.56M	-384.63M	42.01M
Pretax Margin %	43.39%	-13.07%	-	-	-	-
Income Tax+	14.64M	0	0	0	0	0
Effective Tax Rate %	1.19%	1%	1%	1%	1%	1%
Net Income+	172.92M	-32.91M	-55.64M	-52.56M	-384.63M	42.01M
Net Margin %	51.51%	-13.07%	-	-	-	-
Net Income Growth %	-	-1.19%	-0.69%	0.06%	-6.32%	1.11%
Net Income (Continuing)	160.31M	-32.91M	-55.64M	-52.56M	-384.63M	42.01M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	1.28M	5.04M	11.12M	17.09M	0	0
EPS (Diluted)+	1481.04	-547.60	-31.73	-27.25	-4.99	72.93
EPS Growth %	-	-1.37%	0.94%	0.14%	0.82%	15.62%
EPS (Basic)	1495.96	-547.60	-31.73	-27.25	-4.99	77.74
Diluted Shares Outstanding	92.3K	91.62K	1.75M	1.93M	77.07M	575.95K
Basic Shares Outstanding	116K	60K	1.75M	1.93M	77.07M	575K
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	112.14M	20.38M	5.15M	9.84M	6.22M	1.59M
Cash & Short-Term Investments	111.75M	20.17M	5.13M	9.75M	5.16M	13K
Cash Only	6.32M	20.17M	5.13M	9.75M	5.16M	13K
Short-Term Investments	105.42M	0	0	0	0	0
Accounts Receivable	267K	0	0	0	0	0
Days Sales Outstanding	29.03	-	-	-	-	-
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	0	0	26K	92K	1.06M	1.58M
Total Non-Current Assets+	2.21M	838K	1.28M	940K	623K	1.55M
Property, Plant & Equipment	0	0	922K	906K	594K	1.52M
Fixed Asset Turnover	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	1.43M	0	0	0	0	0
Other Non-Current Assets	778K	838K	360K	34K	29K	29K
Total Assets+	114.35M	21.21M	6.44M	10.78M	6.84M	3.14M
Asset Turnover	0.03x	0.12x	-	-	-	-
Asset Growth %	-	-0.81%	-0.7%	0.67%	-0.36%	-0.54%
Total Current Liabilities+	17.5M	4.2M	20.8M	82.57M	13.05M	14.15M
Accounts Payable	1.02M	2.03M	1.19M	7.8M	3.39M	5.91M
Days Payables Outstanding	374.13K	-	-	-	-	-
Short-Term Debt	14.79M	0	15.6M	70.87M	0	0
Deferred Revenue (Current)	0	0	0	0	0	0
Other Current Liabilities	809K	1.25M	1.07M	1.11M	943K	1.07M
Current Ratio	6.41x	4.85x	0.25x	0.12x	0.48x	0.11x
Quick Ratio	6.41x	4.85x	0.25x	0.12x	0.48x	0.11x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	162.73M	220.25M	209.46M	198.62M	146.84M	17.56M
Long-Term Debt	15.16M	72.16M	70.76M	60.43M	0	11.69M
Capital Lease Obligations	0	0	524K	242K	0	1.15M
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	147.56M	148.09M	138.17M	137.95M	146.84M	4.73M
Total Liabilities	180.22M	224.45M	230.26M	281.19M	159.89M	31.71M
Total Debt+	29.95M	72.16M	86.89M	131.53M	278K	12.96M
Net Debt	23.63M	51.99M	81.76M	121.79M	-4.88M	12.94M
Debt / Equity	-	-	-	-	-	-
Debt / EBITDA	-	-	-	-	-	0.18x
Net Debt / EBITDA	-	-	-	-	-	0.18x
Interest Coverage	-7.22x	-1092.53x	-	-	-	-
Total Equity+	-65.87M	-203.23M	-223.82M	-270.41M	-153.04M	-28.57M
Equity Growth %	-	-2.09%	-0.1%	-0.21%	0.43%	0.81%
Book Value per Share	-713.63	-2218.18	-127.64	-140.22	-1.99	-49.60
Total Shareholders' Equity	-67.15M	-208.27M	-234.94M	-287.5M	-153.04M	-28.57M
Common Stock	11K	11K	14K	14K	4K	4K
Retained Earnings	-333.73M	-366.65M	-422.28M	-474.84M	-473.6M	-431.6M
Treasury Stock	-23K	-23K	-23K	-23K	0	0
Accumulated OCI	0	0	0	0	0	0
Minority Interest	1.28M	5.04M	11.12M	17.09M	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-44.73M	-9.46M	-28.43M	-35.58M	-47.83M	-20.29M
Operating CF Margin %	-13.32%	-3.76%	-	-	-	-
Operating CF Growth %	-	0.79%	-2.01%	-0.25%	-0.34%	0.58%
Net Income	160.31M	-32.91M	-55.64M	-52.56M	-384.63M	42.01M
Depreciation & Amortization	1.26M	0	3K	68K	99K	97K
Stock-Based Compensation	5.25M	4.79M	5.22M	5.89M	0	6.25M
Deferred Taxes	-14.64M	0	1.18M	4.75M	0	0
Other Non-Cash Items	-196.96M	17.21M	19.38M	-3K	339.45M	-69.35M
Working Capital Changes	50K	1.45M	1.42M	6.27M	-2.74M	706K
Change in Receivables	-24K	-148K	0	0	0	0
Change in Inventory	-7.39M	0	0	0	0	0
Change in Payables	3.92M	667K	-898K	6.61M	-4.59M	2.52M
Cash from Investing+	-117.29M	-1.26M	-170K	-306K	0	0
Capital Expenditures	-1.69M	0	-170K	-306K	0	0
CapEx % of Revenue	0.5%	-	-	-	-	-
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0
Cash from Financing+	73.21M	24.57M	13.56M	40.51M	14M	15.15M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	-14.2M	-541K	-1.44M	0	0	0
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-46.42M	-9.46M	-28.6M	-35.89M	-47.83M	-20.29M
FCF Margin %	-13.83%	-3.76%	-	-	-	-
FCF Growth %	-	0.8%	-2.02%	-0.25%	-0.33%	0.58%
FCF per Share	-502.91	-103.26	-16.31	-18.61	-0.62	-35.23
FCF Conversion (FCF/Net Income)	-0.26x	0.29x	0.51x	0.68x	0.12x	-0.48x
Interest Paid	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Gross Margin	99.97%	100%	-	-	-	-
Net Margin	5151.03%	-1307.11%	-	-	-	-
Interest Coverage	-7.22x	-1092.53x	-	-	-	-
FCF Conversion	-0.26x	0.29x	0.51x	0.68x	0.12x	-0.48x
Revenue Growth	-	-24.99%	-100%	-	-	-

Frequently Asked Questions

Valuation & Price

AEON Biopharma, Inc. (AEON) has a price-to-earnings (P/E) ratio of 0.0x. This may indicate the stock is undervalued or faces growth challenges.

Growth & Financials

AEON Biopharma, Inc. (AEON) grew revenue by 0.0% over the past year. Growth has been modest.

AEON Biopharma, Inc. (AEON) reported a net loss of $0.0M for fiscal year 2024.

Dividend & Returns

AEON Biopharma, Inc. (AEON) had negative free cash flow of $13.2M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener